Cardio Diagnostics Holdings (CDIO) risk factors, FY2024 10-K

Risks Related to Our Limited Operating History and Early Stage of Growth

1. 01We are a medical diagnostic testing company with a limited operating history and have not yet generated significant revenue from product sales. We have incurred operating losses since our inception and may never achieve or maintain profitability
2. 02We believe our long-term value as a company will be greater if we focus on growth, which may negatively impact our results of operations in the near term
3. 03Our business and the markets in which we operate are new and rapidly evolving, which makes it difficult to evaluate our future prospects and the risks and challenges we may encounter
4. 04Our limited operating history make it difficult to evaluate our future prospects and the risks and challenges we may encounter
5. 05Our quarterly results may fluctuate significantly and may not fully reflect the underlying performance of our business
6. 06We expect to need to raise additional capital to fund our existing operations or develop and commercialize new services or expand our operations
7. 07We may invest in or acquire other businesses, and our business may suffer if we are unable to successfully integrate an acquired business into our company or otherwise manage the growth associated with multiple acquisitions
8. 08We may experience difficulties in managing our growth and expanding our operations

Risks Related to our Business and Industry

1. 09We have an unproven business model with no assurance of significant revenues or operating profit
2. 10The market for epigenetic tests is fairly new and unproven, and it may decline or experience limited growth, which would adversely affect our ability to fully realize the potential of our platform
3. 11The estimates of market opportunity and forecasts of market growth included in this Annual Report on Form 10-K may prove to be inaccurate, and even if the market in which we compete achieves the forecasted growth, our business could fail to grow at similar rates, if at all
4. 12If we are not able to enhance or introduce new products that achieve market acceptance and keep pace with technological developments, our business, results of operations and financial condition could be harmed
5. 13The success of our business depends on our ability to expand into new vertical markets and attract new customers in a cost-effective manner
6. 14Consolidation in the health care industry could have a material adverse effect on our business, financial condition and results of operations
7. 15If we are not able to compete effectively, our business and operating results will be harmed
8. 16Our business depends on customers increasing their use of our solutions, and we may experience loss of customers or decline in their use of our solutions
9. 17Interruptions or performance problems associated with our technology and infrastructure may adversely affect our business and operating results
10. 18We rely on a limited number of suppliers, contract manufacturers, and logistics providers, and our test is performed by a single contract high complexity Clinical Laboratory Improvement Amendments (CLIA) laboratory
11. 19The security of our solutions, networks or computer systems may be breached, and any unauthorized access to our customer data will have an adverse effect on our business and reputation
12. 20Any failure to offer high-quality customer support may adversely affect our relationships with our customers
13. 21The information that we provide to our customers could be inaccurate or incomplete, which could harm our business reputation, financial condition, and results of operations
14. 22Our proprietary applications may not operate properly, which could damage our reputation, give rise to a variety of claims against us, or divert our resources from other purposes, any of which could harm our business and operating results
15. 23If we do not keep pace with technological changes, our solutions may become less competitive, and our business may suffer
16. 24Our growth strategy may not prove viable and expected growth and value may not be realized
17. 25Market and economic conditions may negatively impact our business, financial condition and stock price
18. 26Our success depends upon our ability to adapt to a changing market and our continued development of additional tests and services
19. 27Compliance with changing regulation of corporate governance and public disclosure will result in significant additional expenses

Risks Related to our Business Operations

1. 28We could experience losses or liability not covered by insurance
2. 29Our future growth could be harmed if we lose the services of our key personnel
3. 30If we are unable to hire, retain and motivate qualified personnel, our business will suffer
4. 31If we cannot maintain our corporate culture as it grows, we could lose the innovation, teamwork, passion and focus on execution that it believes contribute to its success, and its business may be harmed
5. 32We may be unable to manage our growth
6. 33Our Board of Directors may change its strategies, policies, and procedures without stockholder approval, and we may become highly leveraged, which may increase our risk of default under our existing or future obligations
7. 34Our business is subject to the risks of earthquakes, fire, floods, pandemics and other natural catastrophic events, and to interruption by man-made problems, such as power disruptions, computer viruses, data security breaches or terrorism
8. 35We may need to seek alternative business opportunities and change the nature of our business
9. 36Any legal proceedings or claims against us could be costly and time-consuming to defend and could harm our reputation regardless of the outcome

Risks Related to our Intellectual Property

1. 37We could incur substantial costs in protecting or defending our intellectual property rights, and any failure to protect or defend our intellectual property could adversely affect our business, results of operations and financial condition
2. 38Assertions by third parties of infringement or other violations by us of its intellectual property rights could result in significant costs and harm our business and operating results
3. 39Certain of our core technology is licensed, and that license may be terminated if we were to breach our obligations under the license
4. 40Some of our technologies incorporate “open-source” software or other similar licensed technologies, which could become unavailable or subject us to increased costs, delays in production or assessment or litigation
5. 41Intellectual property that is in-licensed may have been made using government funding and, thus, may be subject to federal regulations under the Bayh-Dole Act

Risks Related to Government Regulation

1. 42Various bills have been introduced in Congress seeking to substantially revamp the regulation of both LDTs and IVDs, but no legislation has been enacted thus far
2. 43If our products do not receive adequate coverage and reimbursement from third-party payors, our ability to expand access to our tests beyond the initial sales channels will be limited and our overall commercial success will be limited
3. 44Our products may fail to achieve the degree of market acceptance necessary for commercial success

Risks Related to Customer Privacy, Cybersecurity and Data

1. 45Privacy and data security laws and regulations could require us to make changes to our business, impose additional costs on us and reduce the demand for our tests and services
2. 46A pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide, including the re-emergence of the novel strain of coronavirus disease, COVID-19, could adversely affect our business
3. 47Changes in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters could significantly affect our financial results or financial condition

Risks Related to Our Securities

1. 48Our stock price may be volatile and may decline regardless of our operating performance
2. 49An active trading market for our Common Stock may not be created or sustained
3. 50Future sales of Common Stock in the public market could cause our share price to decline significantly, even if our business is doing well
4. 51If securities or industry analysts either do not publish research about us or publish inaccurate or unfavorable research about us, our business, or our market, or if they change their recommendations regarding our Common Stock adversely, the trading price or trading volume of our Common Stock could decline
5. 52Delaware law and provisions in our Charter and Bylaws could make a merger, tender offer, or proxy contest difficult, thereby depressing the trading price of its Common Stock
6. 53Any provision of the Charter or Bylaws that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our Common Stock, and could also affect the price that some investors are willing to pay for our Common Stock
7. 54We currently intend to retain any future earnings to finance the operation and expansion of its business and we do not expect to declare or pay any dividends in the foreseeable future
8. 55We may issue additional shares of our Common Stock or other equity securities without your approval, which would dilute your ownership interests and may depress the market price of our Common Stock
9. 56We may issue additional shares of our Common Stock or other equity securities of equal or senior rank in the future in connection with, among other things, future acquisitions or repayment of outstanding indebtedness, without stockholder approval, in a number of circumstances
10. 57We may redeem the Public Warrants and the Sponsor Warrants prior to their exercise at a time that is disadvantageous to you, as a warrant holder, thereby making your Public Warrants or Sponsor Warrants worthless
11. 58Exercise of our Warrants is dependent upon the trading price of our Common Stock. Because of the disparity between the current stock price and the respective Warrant exercise prices, the Warrants may never be in the money and may expire worthless
12. 59There is no guarantee that the Warrants will be in the money prior to their expiration, and, as such, the Warrants may expire worthless, and we may receive no proceeds from the exercise of the Warrants
13. 60This choice-of-forum provision may limit a warrant holder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us, which may discourage such lawsuits
14. 61Financial reporting obligations of being a public company in the United States are expensive and time-consuming, and our management will be required to devote substantial time to compliance matters
15. 62If we fail to comply with the rules under Sarbanes-Oxley related to accounting controls and procedures in the future, or, if we discover material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult
16. 63We will need to grow the size of our organization and may experience difficulties in managing this growth
17. 64We are an “emerging growth company,” and we cannot be certain that the reduced disclosure requirements applicable to “emerging growth companies” will not make our Common Stock less attractive to investors
18. 65As a “smaller reporting company” we are permitted to provide less disclosure than larger public companies which may make our Common Stock less attractive to investors
19. 66There can be no assurance that we will be able to comply with the continued listing standards of Nasdaq
20. 67We may acquire other companies or technologies, which could divert our management’s attention, result in dilution to our stockholders and otherwise disrupt our operations and adversely affect our operating results